Ulrike Gnad-Vogt

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Martin Alberer, Ulrike Gnad-Vogt, Henoch S. Hong et al. · The Lancet · 2017 · 517 citations

Vaccination, Vaccine Safety, Vaccine Development +6

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

Hubert Kübler, Birgit Scheel, Ulrike Gnad-Vogt et al. · Journal for ImmunoTherapy of Cancer · 2015 · 280 citations · Full text

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Alexandros Papachristofilou, M. Hipp, Ute Klinkhardt et al. · Journal for ImmunoTherapy of Cancer · 2019 · 213 citations · Full text

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Martin Sebastian, Andreas Schröder, Birgit Scheel et al. · Cancer Immunology Immunotherapy · 2019 · 198 citations · Full text

Cancer Immunosurveillance, Phase I/iia Study, Medicine +8

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

Martin Sebastian, Alexandros Papachristofilou, Martin Früh et al. · BMC Cancer · 2014 · 133 citations · Full text